All times shown in GMT - please see the Full Event Guide for CET

8:30 am Virtual Coffee Networking Rooms

9:00 am Chair’s Opening Remarks

9:15 am Industry Leader’s Fireside Chat

10:00 am Discussing Progress, Success, and Future Development in Allogeneic CAR-TCR Cell Therapies

10:30 am Morning Refreshments & Speed Networking

Research & Development

Translation & Clinical

Manufacturing & Commercialisation

Breakthroughs in Solid Tumours: Expanding CAR-TCR Indications

Characterising Cell Types to Select for Highly Efficacious, Cost-Effective Products

Improving Access to CAR-TCR Across Europe

11.00 Developing a qCART Platform to Produce Virus-Free Optimal CAR-T Systems

To see full session details, download the full event guide

Sareina Wu, CEO & CSO, GenomeFrontier Therapeutics

 

11.00 Providing Mechanistic Rationale
for Combination Therapies Through Functional Characterisation

To see full session details, download the full event guide

Marc Van Dijk, CTO, Agenus

 

11.00 Implications of Varied Regulatory
Standards and Hospital Exemption Rules on Drug Product Safety and Commercial Ability

To see full session details, download the full event guide

Annie Hubert, Senior Director, Section & Public Policy, Alliance for Regenerative Medicine

11.30 Equipping T Cells for Trafficking,
Persistence and Maximum Efficacy in the Solid Tumour Setting

To see full session details, download the full event guide

Dolores Schendel, CEO & CSO, Medigene AG

 

11.30 Improving In Vivo Efficacy by Selecting for Favourable Functional, Phenotypic and Metabolic Profiles

To see full session details, download the full event guide

Rogier Reijmers, Principal Scientist, Lumicks

 

11.30 Optimizing recombinant proteins and cytokines for large-scale commercial manufacturing

To see full session details, download the full event guide

Ezequiel Zylberberg, VP Product Development & Planning, Akron Biotech

 

12.00 Enhancing the Safety and Efficacy of CAR-T via Regulation of CAR Expression

To see full session details, download the full event guide

Yoav Ben Yaacov, Co-Founder & CEO, CTG-Pharma

 

12.00 Discussing ‘Gold Standards’ and Innovations in Assay Development

To see full session details, download the full event guide

Eric Alonzo, Associate Director, Analytical Development, bluebird bio

12.00 Can we afford a Cure ? - Payer’s
Perspectives on Value Based Agreements & Innovative Contracting to Reimburse Cell & Gene Therapies

To see full session details, download the full event guide

Omar Ali, Visiting Lecturer, Value Based Pricing & Former Adviser to NICE, University of Portsmouth

 

12:30 pm Lunch & Networking

Research & Development

Translation & Clinical

Manufacturing & Commercialisation

Next-Generation Gene Engineering
& Non-Viral Delivery

Clinical Development for Allogeneic Therapies

Commercial Strategy for Seamless Cell Immunotherapy Delivery in the EU

13.00 Sharing Innovations in Non-Viral Vector Engineering

To see full session details, download the full event guide

Alper Kursunel, Postdoctoral Researcher, Max-Delbrück-Center for Molecular Medicine

 

13.00 Identifying the Best Allogeneic Cell and Donor Populations

To see full session details, download the full event guide

Michael Koslowski, CEO, GammaDelta Therapeutics

 

13.00 Sharing Experience of Point-of-Care CAR T-Cell Production Using a Closed Semi-Automatic Bioreactor

To see full session details, download the full event guide

Maria Castellà, Production Manager, Immunotherapy Platform, Hopital Clinic-BST

 

13:30 Enabling complex cell engineering
with a non-viral delivery platform for cell therapy manufacture

To see full session details, download the full event guide

Shirley O’Dea, CSO, Avectas

 

13:30 Biomarkers to accelerate CART T-cell development

To see full session details, download the full event guide

Akanksha Gupta, Head, Immunology, Biomarker Solution Center, Covance

 

13.30 Challenges and Solutions for GMP CAR T cell manufacturing

To see full session details, download the full event guide

Andrew Kaiser, R&D Senior Manager Cell&Gene Immunotherapy, Miltenyi Biotec

 

14:00 Generating CAR T Cells in Vivo

To see full session details, download the full event guide

Christian Buchholz, Group Leader, Paul-Ehrlich-Institut

 

14:00 Exploiting a Single Receptor for Solid Tumour and Haematological Conditions in Autologous
and Allogeneic Settings

To see full session details, download the full event guide

David Gilham, CSO, Celyad Oncology

 

14:00 Managing the Chain of Identity for Seamless, Patient-Centric Supply

To see full session details, download the full event guide

William Shingler, Senior Director, Patient & Cell Management, Autolus Ltd

 

14:30 Panel Discussion: Future applications of next-generation gene editing for CAR-T

To see full session details, download the full event guide

Marco Alessandrini, CTO, Antion Biosciences

Cécile Bauche, Founder, EVP, CSO, Aratinga.bio

Sarah Meeks, VP Business Development, MaxCyte

14:30 Clinical Development of the Allogeneic PBCAR-T Cells Demonstrating Persistence and Investigating its Correlation with Efficacy

To see full session details, download the full event guide

Christopher Heery, CMO, Precision Biosciences

 

14:30 Considerations and Best Practice in Delivering Cell Immunotherapies with a European Healthcare Authority

To see full session details, download the full event guide

Valeria Judkowski, Senior Director, Quality Assurance Head Site Qualification EU, Kite: A Gilead Company

 

3:00 pm Afternoon Refreshments & Tech Slam

Research & Development

Translation & Clinical

Manufacturing & Commercialisation

Optimising CAR-TCR Design for Improved Efficacy, Safety & Persistence

Clinical Outcomes & Toxicity Management to Minimise Additional Treatment

Advancing Manufacturing & Automation for High Quality Cell Therapy Products at Scale

16:00 The Affinity-Avidity Conundrum: Optimising Receptor-Target Interactions for Improved Safety and Efficacy

To see full session details, download the full event guide

Leah Sibener, Co-Founder & Head of Therapeutic Discovery, 3T Biosciences

 

16:30 Defining Therapeutic Endpoints for Rapid Assessment of Clinical Benefit

To see full session details, download the full event guide

Amit Patel, Consultant, Cellular Therapies and Stem Cell Transplantation, The Christie NHS

 

16:00 Developing CD8-Independent, Next-Generation TCRs for Solid Tumour Indications

To see full session details, download the full event guide

Ali Mohamed, VP, CMC, Immatics Biotechnologies

 

16:30 Engineering Strategies for Fitness in the Solid Tumour Microenvironment

To see full session details, download the full event guide

Francesco Marincola, CSO, Refuge Biotech

 

16:30 Sharing Experience of Clinical
Development of CAR-T in Liquid and Solid Tumour Indications

To see full session details, download the full event guide

Hong Ma, SVP, Clinical Development, CARsgen Therapeutics

 

16:30 Moving to Commercial Readiness with an Analytical Dedicated Platform for T-cell Therapies

To see full session details, download the full event guide

Jef Pinxteren, Director of Process and Analytical Development, Catalent Cell and Gene Therapy

 

17:00 Optimising T Cell Metabolism to Enhance Persistence in Solid Tumours

To see full session details, download the full event guide

Ramon Klein Geltink, Investigator, British Columbia Children’s Hospital

 

17:00 Discussing Success in Pre-Conditioning and Toxicity Management for Safe and Effective Therapeutic Delivery

To see full session details, download the full event guide

Adrian Bot, VP, Translational Medicine, Kite: A Gilead Company

 

17.00 Discussing Innovations in CAR-T
Manufacturing Platforms through Iterative Analysis and Improvement

To see full session details, download the full event guide

Steven Feldman, Director Manufacturing & Process Development, Stanford School of Medicine

 

5:30 pm Chair’s Closing Remarks

6:45 pm End of Day 1